Recruiting
Obesity
RecruitingInvestigational
RO7795068 for Weight Loss in Adults With Obesity or Overweight and Type 2 Diabetes
Investigational
- Disease:Obesity
- Substances:–
Countries:
France
France- Participants:18–64 years · 65+ years
Find therapies in clinical trials near you – page 3
- recruiting
- 3 961
- countries
- 28
- conditions
- 2 103
3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today
537 trials match your criteria
Recruiting
Persistent corneal epithelial defect
RecruitingRegistered drug
Cenegermin Eye Drops for Persistent Corneal Epithelial Defect in Patients with Persistent Corneal Epithelial Defect
Registered drug
- Disease:Persistent corneal epithelial defect
- Substances:CenegerminTropicamide+2
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Cenegermin
Recruiting
Kidney transplant rejection
RecruitingRegistered drugNo placebo
Frexalimab versus Tacrolimus for Prevention of Kidney Transplant Rejection in Adult Kidney Transplant Recipients
Registered drugNo placebo
- Disease:Kidney transplant rejection
- Substances:FrexalimabTacrolimus
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Frexalimab
Recruiting
Acute promyelocytic leukaemia
RecruitingRegistered drugNo placebo
Treatment Study of Arsenic Trioxide, Tretinoin, and Gemtuzumab Ozogamicin for Children and Adolescents with Acute Promyelocytic Leukemia
Registered drugNo placebo
- Disease:Acute promyelocytic leukaemia
- Substances:Arsenic TrioxideCytarabine+5
Countries:France
France- Participants:0–17 years
- Substances:Arsenic Trioxide
Recruiting
Ovarian cancer
RecruitingRegistered drugNo placebo
A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy
Registered drugNo placebo
- Disease:Ovarian cancer
- Substances:BevacizumabSacituzumab Tirumotecan
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Bevacizumab
Recruiting
Homocystinuria
RecruitingInvestigational
A study to evaluate the safety and effectiveness of pegtibatinase in patients aged 12 to 65 years with classical homocystinuria.
Investigational
- Disease:Homocystinuria
- Substances:–
Countries:France
France- Participants:0–17 years · 18–64 years · 65+ years
Recruiting
Juvenile idiopathic arthritis
RecruitingRegistered drugNo placebo
A study to evaluate the safety and effectiveness of filgotinib in children and adolescents aged 8 to 17 years with polyarticular juvenile idiopathic arthritis
Registered drugNo placebo
- Disease:Juvenile idiopathic arthritis
- Substances:Filgotinib
Countries:France
France- Participants:0–17 years
- Substances:Filgotinib
Recruiting
Juvenile idiopathic arthritis
RecruitingRegistered drugNo placebo
A study to evaluate the safety and effectiveness of filgotinib in children and adolescents with juvenile idiopathic arthritis.
Registered drugNo placebo
- Disease:Juvenile idiopathic arthritis
- Substances:Filgotinib
Countries:France
France- Participants:0–17 years
- Substances:Filgotinib
Recruiting
Non-small cell lung cancer
RecruitingRegistered drugNo placebo
Comparing Sotorasib and Pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation
Registered drugNo placebo
- Disease:Non-small cell lung cancer
- Substances:Calcium FolinateCarboplatin+5
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Calcium Folinate
Recruiting
Ovarian epithelial cancer
RecruitingRegistered drugNo placebo
Comparing AZD5335 with Mirvetuximab Soravtansine or a drug combination in patients with platinum-resistant ovarian cancer
Registered drugNo placebo
- Disease:Ovarian epithelial cancer
- Substances:AZD5335Paclitaxel+3
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:AZD5335
Recruiting
Idiopathic pulmonary fibrosis
RecruitingInvestigational
A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis
Investigational
- Disease:Idiopathic pulmonary fibrosis
- Substances:HUMANISED IGG1 LALAPS-YTE MONOCLONAL ANTIBODY AGAINST LYSOPHOSPHATIDIC ACID RECEPTOR 1
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:HUMANISED IGG1 LALAPS-YTE MONOCLONAL ANTIBODY AGAINST LYSOPHOSPHATIDIC ACID RECEPTOR 1
Recruiting
Secondary progressive multiple sclerosis
RecruitingInvestigational
A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis
Investigational
- Disease:Secondary progressive multiple sclerosis
- Substances:Remibrutinib
Countries:France
France- Participants:18–64 years · 65+ years
- Substances:Remibrutinib